Creative BioMart offers assays for exogenous antigen presentation based on methods based on MHC-Associated Peptide Proteomics (MAPPS) analysis and the resolution of MHC complexes in antigen presenting cells (APCs). The service is designed to help researchers identify peptides presented to T cells by APCs, parse MHC complexes isolated from APCs, and discover more details.

The Function of APCs and Presentation of Exogenous Antigen

Identification of the major histocompatibility complex (MHC) class I and II peptides is aimed to evaluate existing quality in terms of the appropriateness of the isolation procedure, as well as parameters used for neoantigen detection. Quantitative proteomics is a powerful way to understand the dynamics of proteins in cells, tissues, or organisms. Bioanalytical methods are developed and applied for immunoproteomics and biomarker analysis in preclinical studies. The main available technique is mass spectrometry (LC-MS). These techniques are used in MHC research in conjunction with multivariate analysis for biomarker identification, such as proteomics and biomarker quantification and validation studies, particularly in immunology and infection.

Fig.1 Regulation of antigen presentation by TLR activation. (Campisi L. 2017)

Our Services

Our services are primarily used to test the function of APC cells in vitro or to analyze immune epitopes in foreign antigen presentation pathways to help researchers better understand your compound. Typically, antigen-presenting cells ingest foreign antigens (microorganisms, proteins, peptide fragments) and process/present peptide fragments that bind to MHC II molecules on the cell surface. Our test platform provides functional testing of APCs and profiling of peptides associated with antigen presentation. Testing is accomplished by immunoaffinity enrichment, lysis, and recovery of peptide-MHC (HLA peptide) molecules from cell lysates. The high-efficiency assay of this service allows us to recover more peptides from MHC (HLA) molecules and analyze them by LC-MS/MS. Our services help clients understand epitopes in biotherapeutics or other proteins of interest that are presented to T cells by MHC (HLA) molecules. Our services provide you with the information you need to understand and manage the immunogenicity of biotherapeutic proteins (peptides) or other protein compounds.

Fig.2 Standard sample workflow for this service.

Advantages of Our Services

• The identified sequences undergo rigorous analysis, and our service can identify true positive peptides with high confidence; Identification was performed by classical methods of peptide-MHC complex extraction, peptide elution and mass spectrometry to identify peptide epitopes.
• Identification was performed by classical methods of peptide-MHC complex extraction, peptide elution and mass spectrometry to identify peptide epitopes.
• High-quality quality control and experienced analytical laboratory technicians.

Our Goals

• Recognize peptides associated with MHC class II molecules (HLA-DR, DP, or DQ);
• To understand the potential immunogenicity of the molecule to be tested in relation to HLA peptide binding;
• Enhanced understanding of the molecule being tested in combination with functional T cell analysis.

The exogenous antigen presentation assays offered by Creative BioMart are performed on APCs, providing customers with additional knowledge about the protein of interest by combining cellular function test assays and peptide quantification methods. Our method combines experimental data from cell function analysis based on traditional methods to help researchers gain a broader perspective. Our experimental platform enables high-quality analytical testing. If you are interested in our services, please contact us for more detailed information.

Reference

• Campisi L. In vitro Antigen-presentation Assay for Self-and Microbial-derived Antigens[J]. Bio-protocol, 2017, 7(11).